IL279246B2 - Preparations containing menaquinone-7 (mk-7) and/or menaquinol to prevent calciphylaxis - Google Patents

Preparations containing menaquinone-7 (mk-7) and/or menaquinol to prevent calciphylaxis

Info

Publication number
IL279246B2
IL279246B2 IL279246A IL27924620A IL279246B2 IL 279246 B2 IL279246 B2 IL 279246B2 IL 279246 A IL279246 A IL 279246A IL 27924620 A IL27924620 A IL 27924620A IL 279246 B2 IL279246 B2 IL 279246B2
Authority
IL
Israel
Prior art keywords
composition
subject
mkh2
administration
vitamin
Prior art date
Application number
IL279246A
Other languages
English (en)
Hebrew (he)
Other versions
IL279246B1 (en
IL279246A (en
Original Assignee
Epizon Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizon Pharma Inc filed Critical Epizon Pharma Inc
Publication of IL279246A publication Critical patent/IL279246A/en
Publication of IL279246B1 publication Critical patent/IL279246B1/en
Publication of IL279246B2 publication Critical patent/IL279246B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL279246A 2018-06-08 2020-12-06 Preparations containing menaquinone-7 (mk-7) and/or menaquinol to prevent calciphylaxis IL279246B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862682794P 2018-06-08 2018-06-08
PCT/US2019/036139 WO2019237054A1 (en) 2018-06-08 2019-06-07 Methods and compositions for preventing or treating calciphylaxis

Publications (3)

Publication Number Publication Date
IL279246A IL279246A (en) 2021-01-31
IL279246B1 IL279246B1 (en) 2023-04-01
IL279246B2 true IL279246B2 (en) 2023-08-01

Family

ID=68763971

Family Applications (1)

Application Number Title Priority Date Filing Date
IL279246A IL279246B2 (en) 2018-06-08 2020-12-06 Preparations containing menaquinone-7 (mk-7) and/or menaquinol to prevent calciphylaxis

Country Status (11)

Country Link
US (7) US10736858B2 (https=)
EP (1) EP3801478A4 (https=)
JP (1) JP2021527129A (https=)
KR (1) KR20210018422A (https=)
CN (1) CN112955131A (https=)
AU (1) AU2019282421B2 (https=)
CA (1) CA3102979A1 (https=)
IL (1) IL279246B2 (https=)
MX (2) MX2020013301A (https=)
SG (1) SG11202012055PA (https=)
WO (1) WO2019237054A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
MX2020013302A (es) 2018-06-08 2021-05-12 Epizon Pharma Inc Métodos y composiciones para prevenir o tratar calcificación de tejido.
US10822295B2 (en) 2018-09-12 2020-11-03 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment
EP3890831A4 (en) * 2019-01-04 2022-09-21 Kaydence Pharma AS COMBINATION THERAPY OF PHOSPHATE BINDERS AND VITAMIN K
CN112691058A (zh) * 2020-12-31 2021-04-23 玉溪健坤生物药业有限公司 一种含还原型维生素k2的牙膏及其制备方法
CN114748486A (zh) * 2022-03-25 2022-07-15 南京盛德生物科技研究院有限公司 一种含有维生素k2改善心血管钙化的药物组合物及其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006607A2 (en) * 2006-07-14 2008-01-17 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
WO2016131993A2 (en) * 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176778A1 (en) 2001-08-03 2005-08-11 Vitak Bv Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification
WO2005030190A1 (en) 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
DE602006020658D1 (de) 2005-06-03 2011-04-28 Nattopharma Asa Verwendung von Vitamin K, um die Verkalkung der Blutgefässe rückgängig zu machen
WO2007095630A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California New ubiquinone analogs and methods of use
GB0817528D0 (en) 2008-09-24 2008-10-29 Syntavit As Process
BR112013009724A2 (pt) 2010-11-01 2016-07-19 Viridis Biopharma Pvt Ltd equilíbrio dinâmico do sistemna nervoso autonômo utilizando a vitamina mk-7
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
US10159787B2 (en) 2012-06-18 2018-12-25 Fresenius Kabi Deutschland Gmbh Port cannula system for puncturing port catheters
WO2014191466A1 (en) 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
GB201314245D0 (en) 2013-08-08 2013-09-25 Kappa Bioscience As Provitamins
EP2868658B1 (en) 2013-11-01 2018-05-02 Dilip Mehta Method of preparation of stereospecific quinone derivatives
BR112017019750A2 (en) 2015-03-20 2018-05-29 Gnosis S.P.A. process for preparing a crystalline form of menaquinol, crystalline form of menaquinol, process for preparing a solid form of menaquinol, pharmaceutical or nutraceutical composition and use of the crystalline form of menaquinol
CN206387961U (zh) 2016-12-30 2017-08-08 孙淑芬 头戴显示设备
IT201700085412A1 (it) * 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
US10368858B1 (en) 2018-01-25 2019-08-06 Ring Orthopedics, Inc. Suture passer
EP3774707A1 (en) 2018-04-06 2021-02-17 Instytut Farmaceutyczny Process of vitamin k 2 derivatives preparation
MX2020013302A (es) 2018-06-08 2021-05-12 Epizon Pharma Inc Métodos y composiciones para prevenir o tratar calcificación de tejido.
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
US10822295B2 (en) 2018-09-12 2020-11-03 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006607A2 (en) * 2006-07-14 2008-01-17 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
WO2016131993A2 (en) * 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CALUWE R ET AL.,, VITAMIN K2 SUPPLEMENTATION IN HAEMODIALYSIS PATIENTS: A RANDOMIZED DOSE-FINDING STUDY. NEPHROLOGY DIALYSIS TRANSPLANTATION, 30 July 2014 (2014-07-30) *
CHRISTIADI D SINGER RF,, CALCIPHYLAXIS IN A DIALYSIS PATIENT SUCCESSFULLY TREATED WITH HIGH-DOSE VITAMIN K SUPPLEMENTATION, 10 November 2017 (2017-11-10) *
KURNATOWSKA I ET AL.,, PLASMA DESPHOSPHO-UNCARBOXYLATED MATRIX GLA PROTEIN AS A MARKER OF KIDNEY DAMAGE AND CARDIOVASCULAR RISK IN ADVANCED STAGE OF CHRONIC KIDNEY DISEASE, 21 April 2016 (2016-04-21) *
SCHEIBER, D. ET AL.,, HIGH-DOSE MENAQUINONE-7 SUPPLEMENTATION REDUCES CARDIOVASCULAR CALCIFICATION IN A MURINE MODEL OF EXTRAOSSEOUS CALCIFICATION, 18 August 2015 (2015-08-18) *

Also Published As

Publication number Publication date
US20240041794A1 (en) 2024-02-08
US20200306207A1 (en) 2020-10-01
EP3801478A1 (en) 2021-04-14
IL279246B1 (en) 2023-04-01
EP3801478A4 (en) 2022-02-23
US20210378987A1 (en) 2021-12-09
KR20210018422A (ko) 2021-02-17
MX2024010211A (es) 2024-09-02
US20200360301A1 (en) 2020-11-19
IL279246A (en) 2021-01-31
US20200306208A1 (en) 2020-10-01
CN112955131A (zh) 2021-06-11
US12433854B2 (en) 2025-10-07
JP2021527129A (ja) 2021-10-11
MX2020013301A (es) 2021-05-12
AU2019282421B2 (en) 2025-01-09
US11065212B2 (en) 2021-07-20
SG11202012055PA (en) 2021-01-28
US11793773B2 (en) 2023-10-24
US10940123B2 (en) 2021-03-09
AU2019282421A1 (en) 2021-01-07
WO2019237054A1 (en) 2019-12-12
US20200306206A1 (en) 2020-10-01
US10925838B2 (en) 2021-02-23
US20190374483A1 (en) 2019-12-12
US10736858B2 (en) 2020-08-11
US10987320B2 (en) 2021-04-27
CA3102979A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
IL279246B2 (en) Preparations containing menaquinone-7 (mk-7) and/or menaquinol to prevent calciphylaxis
US11723882B2 (en) Methods and compositions for preventing or treating tissue calcification
JP2025518709A (ja) ペグ化メナキノール組成物および処置の方法